STADA: Purchase of a generics business in Switzerland successfully concluded

STADA Arzneimittel AG  / Key word(s): Mergers & Acquisitions

31.01.2012 12:06

Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted
by DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

Bad Vilbel, January 31, 2012 - Today, on January 31, 2012, STADA
Arzneimittel AG successfully concluded the purchase of a generics business
in Switzerland from the shareholders of Spirig Pharma AG (see ad hoc
release of May 19, 2011 on the beginning of contract negotiations as well
as the ad hoc update of November 9, 2011 on the signing of the contract,
each published via DGAP).

Sales will be consolidated retroactively in the STADA Group as of January
1, 2012.

The purchase price for this generics business totals approx. CHF 97 million
(applying the exchange rate from the date the ad hoc update on the signing
of the contract was published, approx. EUR 78 million) and also includes
the right to continue marketing acquired products under the Spirig umbrella
brand. The acquired portfolio includes 56 prescription (RX) and 15
non-prescription (OTC) and discretionary prescription (OTX) products. With
regard to the acquired products, STADA estimates the current annual sales
volume to be approx. CHF 42 million (applying the exchange rate from the
date the ad hoc update on the signing of the contract was published,
approx. EUR 34 million) and EBIDTA, adjusted to the business structure
being spun off, to be approx. CHF 9.5 million (applying the exchange rate
from the date the ad hoc update on the signing of the contract was
published, approx. EUR 7.7 million). The acquisition does not include any
production facilities.


Additional information: 
STADA Arzneimittel AG / Corporate Communications / Stadastraße 2-18 / D -
61118 Bad Vilbel /
Tel.: +49(0) 6101 603-113 / Fax: +49(0) 6101 603-506 / E-Mail:
communications@stada.de /
Or visit us in the Internet at www.stada.com.


31.01.2012 DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------------
 
Language:     English
Company:      STADA Arzneimittel AG
              Stadastraße 2-18
              61118 Bad Vilbel
              Germany
Phone:        +49 (0)6101 603- 113
Fax:          +49 (0)6101 603- 506
E-mail:       communications@stada.de
Internet:     www.stada.de
ISIN:         DE0007251803, DE0007251845, 
WKN:          725180, 725184, 
Indices:      MDAX
Listed:       Regulierter Markt in Düsseldorf, Frankfurt (Prime Standard);
              Freiverkehr in Berlin, Hamburg, Hannover, München, Stuttgart
 
End of Announcement                             DGAP News-Service
 
---------------------------------------------------------------------------